Skip to main content

Table 1 Clinical features, monocyte matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinases (TIMP) expression in controls and in Type 2 diabetes patients

From: Monocyte matrix metalloproteinase production in Type 2 diabetes and controls – a cross sectional study

  Control DM CVD-
n 18 22
Age (yrs) 51.7 (8) 56.0 (8) *
Male : Female 14:4 16:6
Diabetes duration (yrs) N/A 6.5 (5.9)
BMI (kg/m2) 26.6 (6.0) 27.4 (7.2)
HbA1c (%) 5.1 (0.4) 7.0 (1.4) **
Fasting plasma glucose (mmol/l) 4.7 (0.7) 8.6 (2.9) **
Treatment   
Aspirin 0 0
Statin 0 0
Diet alone - 6
Sulphonylurea alone - 8
Metformin alone - 3
Combination - 5
MMP-1 (ng/ml) 5.5 (5) 6.4 (5.9)
MMP-3 (ng/ml) 0.0 (1.2) 0.0 (0.8)
MMP-9 (ng/ml) 42.1 (82) 48.2 (51)
TIMP-1 (ng/ml) 192.9 (108) 163.0 (111)
  1. * p < 0.05 compared to controls ** p < 0.0001 compared to controls. Clinical data shown as mean (SD), MMP and TIMP-1 data shown as median (IQR)